Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Natera (NTRA) and Argenx Se (ARGX)
Stifel Nicolaus Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)
Viking Therapeutics Analyst Ratings
Viking Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $90 Price Target
Viking Therapeutics Analyst Ratings
Truist Securities Maintains Buy on Viking Therapeutics, Maintains $120 Price Target
Viking Therapeutics Analyst Ratings
Raymond James Upgrades Viking Therapeutics to Strong Buy, Raises Price Target to $116
Raymond James Company: The Viking Therapeutics (VKTX.US) rating was raised from superior to the market to a strong buy rating, and the target price was adjusted from $115.00 to $116.00.
Viking Therapeutics Analyst Ratings
Truist Securities Reiterates Buy on Viking Therapeutics, Maintains $120 Price Target
Viking Therapeutics (VKTX) Receives a Buy From Truist Financial
Viking Therapeutics (VKTX) Gets a Buy From Truist Financial
Analysts Conflicted on These Healthcare Names: Viking Therapeutics (VKTX) and Bristol-Myers Squibb (BMY)
Buy Rating Affirmed for Viking Therapeutics Amidst Strong Clinical Progress and Strategic Moves
HC Wainwright & Co. : The Viking Therapeutics (VKTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $90.00.
Viking Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $90 Price Target
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Acrivon Therapeutics, Inc. (ACRV) and Gain Therapeutics (GANX)